LONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the Stifel 2026 Healthcare Conference November 10–12, 2026. Robert J. Dempsey, Chief Executive Officer, is scheduled to present at 9:20 a.m. ET on Thursday, November 12, 2026, at the Stifel 2026 Hea
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Detailed price information for Okyo Pharma Limited ADR (OKYO-Q) from The Globe and Mail including charting and trades.
Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal painLONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in
Detailed price information for Okyo Pharma Limited ADR (OKYO-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.